PMLiVE21h
Eli Lilly and Alchemab Therapeutics partner to develop new ALS therapies
Eli Lilly and Alchemab Therapeutics have partnered to develop new therapies for amyotrophic lateral sclerosis (ALS). The ...
PMLiVE2d
Axsome announces positive results from phase 3 Alzheimer’s disease programme
In its latest update of AXS-05, Axsome reported that the 295-patient phase 3 ACCORD-2 trial met its primary endpoint, with ...
PMLiVE2d
Bristol Myers Squibb’s Sotyktu shows promise in phase 3 psoriatic arthritis trials
Bristol Myers Squibb (BMS) has shared positive top-line results from two late-stage studies of its oral TYK2 inhibitor ...